BR112019005144A2 - sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso. - Google Patents

sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso.

Info

Publication number
BR112019005144A2
BR112019005144A2 BR112019005144-9A BR112019005144A BR112019005144A2 BR 112019005144 A2 BR112019005144 A2 BR 112019005144A2 BR 112019005144 A BR112019005144 A BR 112019005144A BR 112019005144 A2 BR112019005144 A2 BR 112019005144A2
Authority
BR
Brazil
Prior art keywords
protein
interest
expression regulatory
expressing
cell
Prior art date
Application number
BR112019005144-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Zangi Lior
Magadum Ajit
Original Assignee
Icahn School Of Medicine At Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Of Medicine At Mount Sinai filed Critical Icahn School Of Medicine At Mount Sinai
Publication of BR112019005144A2 publication Critical patent/BR112019005144A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112019005144-9A 2016-09-16 2017-09-18 sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso. BR112019005144A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395701P 2016-09-16 2016-09-16
US62/395,701 2016-09-16
PCT/US2017/052035 WO2018053414A1 (en) 2016-09-16 2017-09-18 Cell-specific expression of modrna

Publications (1)

Publication Number Publication Date
BR112019005144A2 true BR112019005144A2 (pt) 2019-06-04

Family

ID=61619271

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005144-9A BR112019005144A2 (pt) 2016-09-16 2017-09-18 sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso.

Country Status (9)

Country Link
US (3) US11299749B2 (cg-RX-API-DMAC10.html)
EP (2) EP3512567B1 (cg-RX-API-DMAC10.html)
JP (2) JP7432362B2 (cg-RX-API-DMAC10.html)
CN (1) CN110177578B (cg-RX-API-DMAC10.html)
AU (2) AU2017326535B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019005144A2 (cg-RX-API-DMAC10.html)
CA (1) CA3036710A1 (cg-RX-API-DMAC10.html)
ES (1) ES2967788T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018053414A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017326535B2 (en) * 2016-09-16 2023-08-24 Icahn School Of Medicine At Mount Sinai Cell-specific expression of modrna
CN111971392A (zh) * 2018-03-30 2020-11-20 国立大学法人京都大学 细胞的制造方法
EP4010481A4 (en) 2019-08-09 2023-09-20 Nutcracker Therapeutics, Inc. MICROFLUIDIC DEVICE AND METHODS OF USE
US12606822B2 (en) 2019-11-07 2026-04-21 Icahn School Of Medicine At Mount Sinai Synthetic modified RNA and uses thereof
US20220347204A1 (en) * 2019-11-11 2022-11-03 Icahn School Of Medicine At Mount Sinai Gene delivery systems for treatment of heart failure
EP4351623B1 (en) 2021-06-09 2026-08-05 Icahn School of Medicine at Mount Sinai Gene combination as a broad spectrum antiviral
US20240384277A1 (en) * 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
CN114085834A (zh) * 2021-11-16 2022-02-25 珠海中科先进技术研究院有限公司 一种癌细胞导向电路组及应用
US20250290056A1 (en) * 2022-04-27 2025-09-18 The Penn State Research Foundation Modrna-based cas endonuclease and base editor and uses thereof
US20230364267A1 (en) * 2022-05-13 2023-11-16 The Uab Research Foundation Pre-clinical modified rna approaches used in large animals for muscle and vascular regeneration
EP4282963A1 (en) * 2022-05-23 2023-11-29 Eberhard Karls Universität Tübingen, Medizinische Fakultät Nucleic acid modified biological cell with expansion-dependent gene expression
WO2024015729A1 (en) * 2022-07-11 2024-01-18 Icahn School Of Medicine At Mount Sinai Regulatory system for expression of a gene of interest in a target cell and method of use thereof
EP4562163A1 (en) * 2022-07-26 2025-06-04 ModernaTX, Inc. Engineered polynucleotides for temporal control of expression
CN116785501A (zh) * 2022-08-04 2023-09-22 上海交通大学医学院附属上海儿童医学中心 促进心脏组织修复的modRNA转染改造的细胞及其应用
WO2024151975A1 (en) 2023-01-13 2024-07-18 Igor Lednev Detecting degradation of a polynucleotide by raman spectroscopy
CN119120571B (zh) * 2024-09-11 2026-03-17 武汉科技大学 一种治疗hiv感染的靶向外泌体嵌合抗原受体分子的构建及其应用
WO2026107144A1 (en) 2024-11-14 2026-05-21 Icahn School Of Medicine At Mount Sinai Rna sequence for expressing protein in cardiomyocytes
WO2026147861A1 (en) 2024-12-30 2026-07-09 Icahn School Of Medicine At Mount Sinai System for gene expression in colon cancer cells and method of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331526T2 (de) 1992-11-18 2002-10-24 Arch Development Corp., Chicago Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
US20090005336A1 (en) * 2007-05-08 2009-01-01 Zhiguo Wang Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
ES2769129T3 (es) * 2009-12-07 2020-06-24 Univ Pennsylvania Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células
US9458509B2 (en) * 2010-07-22 2016-10-04 President And Fellows Of Harvard College Multiple input biologic classifier circuits for cells
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
EP2584040A1 (en) * 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
CA2915627A1 (en) * 2012-06-15 2013-12-19 The General Hospital Corporation Inhibitors of micrornas that regulate production of atrial natriuretic peptide (anp) as therapeutics and uses thereof
WO2014093574A1 (en) * 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
US10538740B2 (en) 2014-03-20 2020-01-21 Kyoto University Method for sorting cardiomyocytes
WO2016040395A1 (en) * 2014-09-08 2016-03-17 Massachusetts Institute Of Technology Rna-based logic circuits with rna binding proteins, aptamers and small molecules
AU2017326535B2 (en) * 2016-09-16 2023-08-24 Icahn School Of Medicine At Mount Sinai Cell-specific expression of modrna

Also Published As

Publication number Publication date
US11299749B2 (en) 2022-04-12
CA3036710A1 (en) 2018-03-22
CN110177578B (zh) 2024-02-13
EP4316587A2 (en) 2024-02-07
WO2018053414A1 (en) 2018-03-22
JP7432362B2 (ja) 2024-02-16
AU2017326535B2 (en) 2023-08-24
ES2967788T3 (es) 2024-05-03
EP3512567B1 (en) 2023-11-01
US20190203226A1 (en) 2019-07-04
EP3512567C0 (en) 2023-11-01
US20220220501A1 (en) 2022-07-14
CN110177578A (zh) 2019-08-27
US12215336B2 (en) 2025-02-04
JP2019528736A (ja) 2019-10-17
US20250154523A1 (en) 2025-05-15
EP4316587A3 (en) 2024-04-24
EP3512567A4 (en) 2020-03-18
AU2023270313A1 (en) 2024-01-04
EP3512567A1 (en) 2019-07-24
JP2023123520A (ja) 2023-09-05
AU2017326535A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
EP4316587A3 (en) Cell-specific expression of modrna
BR112019006384A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
BR112018073606A2 (pt) polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
BR112018074325A2 (pt) anticorpo para ligação a receptor de interleucina 4
BR112018016443A2 (pt) sistema de transposon replicativo
BR112022002695A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR112018076394A2 (pt) genes de minidistrofina otimizados e cassetes de expressão e seu uso
BR112019007309A2 (pt) anticorpos anti-c1s e métodos de uso dos mesmos
BR112019006388A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112017014917A2 (pt) elementos regulatórios pós-transcricionais modificados de hepatite
BR112018010639A2 (pt) método de transfecção transitória para produção retroviral.
BR112018075399A2 (pt) sistema de distribuição viral não integrativo e métodos relacionados a este
BR112019011582A2 (pt) anticorpos e métodos de utilização dos mesmos
BR112019012964A2 (pt) polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos
BR112021025130A2 (pt) Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos
CL2020000937A1 (es) Anticuerpo multiespecífico.
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112019000015A2 (pt) distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112019008369A2 (pt) ácidos ribonucleicos mensageiros para intensificar respostas imunes e métodos para uso dos mesmos
BR112015028493A2 (pt) Métodos para preparar células t para imunoterapia, célula t isolada, seu uso e composição farmacêutica

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI NO 334 DE 24/09/2020, QUANTO AOS PRAZOS VENCIDOS ENTRE 16/09/2020 A 25/09/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]